Effect of 4-Fluoro-N-(4-Sulfamoylbenzyl) Benzene Sulfonamide on Acquisition and Expression of Nicotine-Induced Behavioral Sensitization and Striatal Adenosine Levels.
Adenosine
/ antagonists & inhibitors
Administration, Oral
Animals
Behavior, Animal
/ drug effects
Benzene Derivatives
/ administration & dosage
Dose-Response Relationship, Drug
Injections, Intraperitoneal
Male
Mice
Mice, Inbred BALB C
Nicotine
/ administration & dosage
Nicotinic Antagonists
/ administration & dosage
Sulfonamides
/ administration & dosage
4-fluoro-N-(4-sulfamoylbenzyl) benzene-sulfonamide (4-FBS)
HPLC
adenosine
drug addiction
locomotor activity
nicotine sensitization
pharmacotherapy
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
07
2020
accepted:
28
08
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
8
7
2021
Statut:
epublish
Résumé
Behavioral sensitization is a phenomenon that develops from intermittent exposure to nicotine and other psychostimulants, which often leads to heightened locomotor activity and then relapse. Sulfonamides that act as carbonic anhydrase inhibitors have a documented role in enhancing dopaminergic tone and normalizing neuroplasticity by stabilizing glutamate release. The aim of the current study was to explore synthetic sulfonamides derivative 4-fluoro-N-(4-sulfamoylbenzyl) benzene-sulfonamide (4-FBS) (with documented carbonic anhydrase inhibitory activity) on acquisition and expression of nicotine-induced behavioral sensitization. In the acquisition phase, selected 5 groups of mice were exposed to saline or nicotine 0.5mg/kg intraperitoneal (i.p) for 7 consecutive days. Selected 3 groups were administered with 4-FBS 20, 40, and 60 mg/kg p.o. along with nicotine. After 3 days of the drug-free period, ie, day 11, a challenge dose of nicotine was injected to all groups except saline and locomotor activity was recorded for 30 minutes. In the expression phase, mice were exposed to saline and nicotine only 0.5 mg/kg i.p for 7 consecutive days. After 3 days of the drug-free period, ie, day 11, 4-FBS at 20, 40, and 60 mg/kg were administered to the selected groups, one hour after drug a nicotine challenge dose was administered, and locomotion was recorded. At the end of behavioral experiments, all animals were decapitated and the striatum was excised and screened for changes in adenosine levels, using HPLC-UV. Taken together, our findings showed that 4-FBS in all 3 doses, in both sets of experiments significantly attenuated nicotine-induced behavioral sensitization in mice. Additionally, 4-FBS at 60mg/kg significantly lowered the adenosine level in the striatum. The behavioral and adenosine modulation is promising, and more receptors level studies are warranted to explore the exact mechanism of action of 4-FBS.
Identifiants
pubmed: 32982182
doi: 10.2147/DDDT.S270025
pii: 270025
pmc: PMC7505708
doi:
Substances chimiques
Benzene Derivatives
0
Nicotinic Antagonists
0
Sulfonamides
0
Nicotine
6M3C89ZY6R
Adenosine
K72T3FS567
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3777-3786Informations de copyright
© 2020 Ur Rehman et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Neuroscience. 1987 Sep;22(3):813-26
pubmed: 2825070
J Biol Chem. 1998 Feb 20;273(8):4718-24
pubmed: 9468534
Int J Mol Sci. 2020 Jun 21;21(12):
pubmed: 32575871
Eur J Pharmacol. 2002 Jun 20;446(1-3):75-82
pubmed: 12098587
Brain Res. 2000 Jun 9;867(1-2):250-4
pubmed: 10837822
Neuropharmacology. 2006 Sep;51(3):631-40
pubmed: 16793068
Neuropharmacology. 2014 Jun;81:318-26
pubmed: 24632528
J Neurosci. 1999 May 15;19(10):3723-30
pubmed: 10234004
Drug Alcohol Depend. 2013 Oct 1;132(3):479-85
pubmed: 23570817
Trends Neurosci. 1997 Oct;20(10):482-7
pubmed: 9347617
Biochem Pharmacol. 2001 Feb 15;61(4):443-8
pubmed: 11226378
J Neurochem. 2001 Nov;79(3):463-84
pubmed: 11701750
Neuroscience. 1988 Jul;26(1):83-100
pubmed: 2971144
Prog Neurobiol. 2008 Apr;84(4):329-42
pubmed: 18242816
Brain Res. 2006 Mar 10;1077(1):67-80
pubmed: 16516871
Psychopharmacology (Berl). 2004 Dec;177(1-2):100-10
pubmed: 15338099
Synapse. 2011 Aug;65(8):708-14
pubmed: 21108239
Neurosci Lett. 2009 Apr 17;454(1):91-6
pubmed: 19429061
Neuroreport. 1994 Dec 30;6(1):73-6
pubmed: 7703433
Bioorg Med Chem Lett. 2006 Jul 15;16(14):3642-5
pubmed: 16697192
J Pharm Pharmacol. 2008 Nov;60(11):1409-30
pubmed: 18957161
Pol J Pharmacol. 2002 Mar-Apr;54(2):119-26
pubmed: 12139108
Brain Sci. 2013 Feb 15;3(1):159-76
pubmed: 24961312
J Comp Neurol. 1998 Sep 21;399(2):229-40
pubmed: 9721905
J Neurophysiol. 2000 Mar;83(3):1307-14
pubmed: 10712458
Expert Opin Ther Pat. 2013;23(6):681-91
pubmed: 23488823
Eur Neuropsychopharmacol. 2015 Jun;25(6):933-43
pubmed: 25795518
Eur J Pharmacol. 2017 Oct 5;812:28-37
pubmed: 28668504
Biol Psychiatry. 2009 May 15;65(10):841-5
pubmed: 19103434
Neuropsychopharmacology. 2000 Oct;23(4 Suppl):S50-9
pubmed: 11008067
Brain Res Brain Res Rev. 1991 Sep-Dec;16(3):223-44
pubmed: 1665095
Science. 2004 Nov 5;306(5698):1029-32
pubmed: 15528443
Eur J Pharmacol. 2007 Mar 29;560(1):42-8
pubmed: 17292882
Expert Opin Ther Pat. 2013;23(6):717-24
pubmed: 23514045
Yonsei Med J. 2008 Apr 30;49(2):175-88
pubmed: 18452252
Eur J Neurosci. 2020 Feb;51(3):781-792
pubmed: 31613395
J Pharm Biomed Anal. 2001 Mar;24(5-6):1143-6
pubmed: 11248511
Addiction. 2004 Jan;99(1):29-38
pubmed: 14678060
Neuroscience. 2002;115(3):743-51
pubmed: 12435413
Angew Chem Int Ed Engl. 2014 Apr 14;53(16):4231-5
pubmed: 24623670
J Pain. 2014 Apr;15(4):395-406
pubmed: 24412803
Crit Rev Neurobiol. 2003;15(3-4):235-74
pubmed: 15248812
Addict Sci Clin Pract. 2011 Jul;6(1):4-16
pubmed: 22003417
Neurosci Biobehav Rev. 1997 Mar;21(2):207-17
pubmed: 9062944
J Psychopharmacol. 2020 Jan;34(1):137-144
pubmed: 31694445
Int J Mol Sci. 2020 Jun 22;21(12):
pubmed: 32580510
Bioorg Med Chem. 2015 May 15;23(10):2435-44
pubmed: 25865133
Brain Res Brain Res Rev. 2000 Sep;33(2-3):258-74
pubmed: 11011069
PLoS One. 2013 Nov 28;8(11):e80902
pubmed: 24312250
Synapse. 2009 Jan;63(1):15-21
pubmed: 18925656
Neuron. 1996 Mar;16(3):631-9
pubmed: 8785060
Nicotine Tob Res. 2016 May;18(5):1171-9
pubmed: 26476459
J Neurosci. 1997 Jul 15;17(14):5271-80
pubmed: 9204911
Prog Neurobiol. 2007 Dec;83(5):332-47
pubmed: 17532111
Clin Pharmacol Ther. 2008 Apr;83(4):531-41
pubmed: 18305452
Addiction. 2010 Aug;105(8):1362-80
pubmed: 20653619
Addict Biol. 2015 Mar;20(2):248-58
pubmed: 24251901
Eur J Pharmacol. 1994 Feb 21;253(1-2):95-9
pubmed: 8013554
Neuropharmacology. 1996;35(11):1503-19
pubmed: 9025098
Biol Psychiatry. 2010 Jan 1;67(1):81-4
pubmed: 19717140
Neuroendocrinology. 2002 Mar;75(3):201-8
pubmed: 11914592
Nat Rev Neurosci. 2013 Apr;14(4):278-91
pubmed: 23511908
Curr Med Chem. 2012;19(3):317-55
pubmed: 22335511
Pharmacol Rev. 2011 Jun;63(2):348-65
pubmed: 21490129
Pharm Biol. 2012 Oct;50(10):1310-6
pubmed: 22873194
Prog Neurobiol. 2007 Dec;83(5):277-92
pubmed: 17646043